Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MK-4280 |
Trade Name | |
Synonyms | MK4280|MK 4280|favezelimab |
Drug Descriptions |
MK-4280 (favezelimab) is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (PMID: 29359507, PMID: 29427592). |
DrugClasses | Immune Checkpoint Inhibitor 149 LAG3 Antibody 18 |
CAS Registry Number | 2231068-83-8 |
NCIT ID | C142077 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Irinotecan + MK-4280 + Pembrolizumab | Irinotecan MK-4280 Pembrolizumab | 0 | 0 |
Lenvatinib + MK-4280 + Pembrolizumab | Lenvatinib MK-4280 Pembrolizumab | 0 | 0 |
MK-4280 | MK-4280 | 0 | 1 |
MK-4280 + Paclitaxel + Pembrolizumab | MK-4280 Paclitaxel Pembrolizumab | 0 | 0 |
MK-4280 + Pembrolizumab | MK-4280 Pembrolizumab | 0 | 4 |